RSC Advances
Paper
159.6 (CH), 151.6 (C), 141.9 (C), 126.6 (CH), 122.8 (CH), 121.0 (2H, s, CH2); dC (100 MHz; CDCl3) 165.0 (C), 159.3 (CH), 136.5
(CH), 115.9 (CH), 112.8 (CH), 55.9 (CH3). Data recorded matches (C), 128.4 (CH), 127.9 (CH), 127.9 (CH), 115.1 (CH), 69.0 (CH2).
literature.13
2-(4-Methylphenoxy)pyrazine 9
2-(3,4-Dimethylphenoxy)pyrimidine 5
Following the general procedure, 2-chloropyrazine (156 mL, 1.75
Following the general procedure, 2-chloropyrimidine (200 mg,
mmol), p-cresol (184 mL, 1.75 mmol) and potassium carbonate
1.75 mmol), 3,4-dimethylphenol (214 mg, 1.75 mmol) and
(483 mg, 3.50 mmol) in DMSO (1 mL) at 100 ꢀC for 17 h gave the
potassium carbonate (483 mg, 3.50 mmol) in DMSO (1 mL) at
title compound as a beige crystalline solid (302 mg, 93%); mp 38–
100 ꢀC for 17 h gave aer purication by chromatography (1 : 4
40 ꢀC; (found; M+, 187.0875. C11H10N2O requires 187.0866); nmax
ethyl acetate/light petroleum) the title compound as a yellow oil
(CHCl3)/cmꢁ1 3061, 1580, 1532, 1504, 1465, 1401; dH (400 MHz;
(235 mg, 67%); (lit.,13 mp 49–51 ꢀC); (found; M+, 201.1028.
CDCl3) 8.43 (1H, d, J 1.1, 3H), 8.25 (1H, d, J 2.7, 6H), 8.11 (1H,
C
12H13N2O requires 201.1022); nmax (CHCl3)/cmꢁ1 3004, 1614,
dd, J 2.7, 1.1, 5H), 7.24 (2H, d, J 8.5, ArH), 7.07 (2H, d, J 8.5, ArH),
2.39 (3H, s, CH3); dC (100 MHz; CDCl3) 160.5 (C), 150.7 (C), 141.1
(CH), 138.3 (CH), 135.8 (CH), 135.1 (C), 130.3 (CH), 121.1 (CH),
20.9 (CH3).
1571, 1500, 1450, 1410; dH (400 MHz; CDCl3) 8.58 (2H, m, ArH,
4H, 6H), 7.20 (1H, d, J 7.8, ArH), 7.04–7.00 (2H, m, ArH), 6.98
(1H, d, J 7.8, ArH), 2.30 (3H, s, CH3), 2.29 (3H, s, CH3); dC (100
MHz; CDCl3) 165.7 (C), 159.7 (CH), 150.8 (C), 138.2 (C), 133.9
(C), 130.7 (CH), 122.6 (CH), 118.8 (CH), 115.9 (CH), 20.0 (CH3),
19.3 (CH3). Data recorded matches literature.13
2-(2-Methylphenoxy)pyrazine 10
Following the general procedure, 2-chloropyrazine (156 mL, 1.75
mmol), o-cresol (180 mL, 1.75 mmol) and potassium carbonate
2-Phenoxypyrimidine 6
Following the general procedure, 2-chloropyrimidine (200 mg, (483 mg, 3.50 mmol) in DMSO (1 mL) at 100 ꢀC for 17 h gave the
ꢀ
1.75 mmol), phenol (165 mg, 1.75 mmol) and potassium title compound as a yellow solid (295 mg, 91%); mp 40–42 C;
carbonate (483 mg, 3.50 mmol) in DMSO (1 mL) at 100 ꢀC for 17 (found; M+, 187.0868. C11H10N2O requires 187.0866); nmax
h gave aer purication by chromatography (1 : 9 ethyl acetate/ (CHCl3)/cmꢁ1 2915, 1578, 1531, 1485, 1466, 1397; dH (400 MHz;
light petroleum) the title compound as a yellow crystalline solid CDCl3) 8.45 (1H, d, J 1.2, 3H), 8.27 (1H, d, J 2.8, 6H), 8.11 (1H,
(195 mg, 65%); mp 84–86 ꢀC (lit.,13 mp 85–86 ꢀC); nmax (CHCl3)/ dd, J 2.8, 1.2, 5H), 7.34–7.27 (2H, m, ArH), 7.22 (1H, dt, J 7.5, 1.5,
cmꢁ1 3062, 1592, 1568, 1489, 1453, 1401; dH (400 MHz; CDCl3) ArH), 7.09 (1H, dd, J 7.8, 1.5, CH3); dC (100 MHz; CDCl3) 160.2
8.58 (2H, d, J 4.8, 4H, 6H), 7.46 (1H, t, J 7.7, ArH), 7.28 (1H, t, J (C), 151.3 (C), 141.3 (CH), 138.1 (CH), 135.3 (CH), 131.6 (CH),
7.8, ArH), 7.25–7.21 (2H, m, ArH), 7.05 (1H, t, J 4.8, 5H), 6.89 130.7 (C), 127.3 (CH), 125.9 (CH), 121.7 (CH), 16.3 (CH3). Data
(1H, d, J 7.8, ArH); dC (100 MHz; CDCl3) 165.3 (C), 159.8 (CH), recorded matches literature.11
152.3 (C), 129.8 (CH), 125.7 (CH), 121.7 (CH), 155.6 (CH), 111.6
(CH). Data recorded matches literature.13
2-(4-(Pyrazin-2-yloxy)phenyl)ethanol 11
Following the general procedure, 2-chloropyrazine (156 mL, 1.75
mmol), 2-(4-hydroxyphenyl)ethanol (242 mg, 1.75 mmol) and
potassium carbonate (483 mg, 3.50 mmol) in DMSO (1 mL) at
100 ꢀC for 17 h gave aer purication by chromatography (ethyl
acetate) the title compound as a colourless crystalline solid (311
mg, 87%); mp 65–67 ꢀC (lit.,14 mp 75 ꢀC); (found; M+, 239.0779.
2-(2-Furylmethoxy)pyrimidine 7
Following the general procedure, 2-chloropyrimidine (200 mg,
1.75 mmol), furfuryl alcohol (156 mL, 1.75 mmol) and potassium
carbonate (483 mg, 3.50 mmol) in DMSO (1 mL) at 100 ꢀC for 17
h gave the title compound as a brown oil (156 mg, 51%); (found;
M+, 199.0987. C9H9N2O2Na+ requires 199.0483); nmax (CHCl3)/
cmꢁ1 3009, 1578, 1568, 1502, 1449, 1425; dH (400 MHz; CDCl3)
8.55 (2H, d, J 4.8, 4H, 6H), 7.44 (1H, m, ArH), 6.97 (1H, t, J 4.8,
5H), 6.50–6.49 (1H, m, ArH), 6.38 (1H, m, ArH), 5.41 (2H, s,
CH2); dC (100 MHz; CDCl3) 165.5 (C), 159.3 (CH), 149.9 (C), 143.0
(CH), 115.3 (CH), 110.5 (CH), 107.4 (CH), 61.1 (CH2).
C
12H12N2O2 requires 239.0797); nmax (CHCl3)/cmꢁ1 3619, 3441,
3066, 3008, 2951, 1581; dH (400 MHz; CDCl3) 8.42 (1H, d, J 1.2,
3H), 8.25 (1H, d, J 2.6, 5H), 8.09 (1H, dd, J 2.6, 1.2, 6H), 7.30 (2H,
d, J 8.5, ArH), 7.12 (2H, d, J 8.5, ArH), 3.88 (2H, t, J 6.5, CH2), 2.90
(2H, t, J 6.5, CH2); dC (100 MHz; CDCl3) 160.3 (C), 151.5 (C),
141.1 (CH), 138.4 (CH), 135.9 (CH), 135.9 (CH), 130.4 (CH), 121.3
(CH), 63.5 (CH2), 38.6 (CH2). Data recorded matches literature.14
2-Benzyloxypyrimidine 8
Following the general procedure, 2-chloropyrazine (156 mL, 1.75
mmol), benzyl alcohol (181 mL, 1.75 mmol) and potassium
ICP-MS analysis
carbonate (483 mg, 3.50 mmol) in DMSO (1 mL) at 100 ꢀC for 17 Approximately 100 mg of potassium carbonate sample material
h gave evaporation of the remaining benzyl alcohol the title was dissolved and diluted to 50 mL of sample matrix solution
compound as a colourless oil (115 mg, 35%); (found; M+, (5% hydrochloric acid, 1% hydrogen peroxide aqueous solu-
187.0882. C11H10N2O requires 187.0866); nmax (CHCl3)/cmꢁ1 tion), and analysed by ICP-MS (ICP-MS X-SERIES 2 Thermo
3010, 1579, 1567, 1497, 1458, 1424; dH (400 MHz; CDCl3) 8.56 analyser). The instrument limit of quantitation was determined
(2H, d, J 4.8, 4H, 6H), 7.52 (1H, dd, J 7.2, 1.5, ArH), 7.39 (2H, dt, J by 10 times injection of blank matrix solution as 21 ppb and 7
7.2, 1.5, ArH), 7.35–7.31 (1H, m, ArH), 6.97 (1H, t, J 4.8, 5H), 5.48 ppb for Cu and Pd respectively.
28076 | RSC Adv., 2014, 4, 28072–28077
This journal is © The Royal Society of Chemistry 2014